 |
Tranzyme
Pharma to Present New In Vivo Data on its Novel GI Compounds at
Digestive Disease Week 2006
RESEARCH TRIANGLE PARK, N.C. and
SHERBROOKE, Québec (May 17, 2006) -Tranzyme Pharma, a leading
biopharmaceutical company developing small molecule therapeutics
for the treatment of gastrointestinal (GI) and metabolic
diseases, announced today that its Vice President of Drug
Discovery, Dr. Graeme Fraser, will present results from
preclinical proof-of-concept studies on two of the Company’s
novel development candidates at the upcoming 2006 Digestive
Disease Week to be held at Los Angeles, CA. The new data will be
highlighted in two oral presentations to be given on Sunday, May
21.
In the first presentation entitled “Ghrelin Agonist Activity in
a Rat Model of Postoperative Ileus and Opioid-Delayed
Gastrointestinal Motility”, Dr. Fraser will discuss efficacy
observed in rat models with the Company’s novel gastroprokinetic
ghrelin agonist, TZP-101. In this study, TZP-101 was shown to
restore impaired gastric emptying and delayed small intestinal
transit caused by abdominal surgery, morphine, and a combination
of both surgery and morphine. The study was directed by Dr.
Beverly Greenwood-Van Meerveld, a leading GI investigator and
Director of the Oklahoma Center for Neuroscience at the
University of Oklahoma Health Sciences Center.
Tranzyme Pharma recently announced the successful completion of
a Phase I clinical trial of TZP-101. This product is in clinical
development as a first-in-class therapy for the treatment of
post-operative ileus and other GI motility disorders.
The second presentation entitled “Motilin Receptor Antagonism
Attenuates Naturally Occurring MMCs and Reverses
Motilin-Impaired Gastric Accommodation in Conscious Dogs”
presents ground-breaking proof-of-concept data for the Company’s
motilin antagonist program. In this study, the compound was
shown to delay, in a dose-dependent manner, the appearance of
Phase III contractions of the migrating motor complex (MMC) in
fasted dogs and reduce postprandial contractions in fed dogs.
The data confirm the hypothesis that motilin is an endocrine
regulator of the MMC and further imply that motilin plays a role
in the regulation of postprandial activity. These data suggest
that motilin antagonism has therapeutic potential in the
treatment of GI disorders characterized by hypermotility or
absorptive disorders in the gut. This study was conducted in
collaboration with researchers at Johnson & Johnson
Pharmaceutical Research and Development (Beerse, Belgium).
Tranzyme Pharma is developing its proprietary motilin antagonist,
TZP-201, as a treatment for functional GI disorders such as
diarrhea-type irritable bowel syndrome and functional dyspepsia.
“We are pleased to present these new findings of the Company’s
candidate GI therapeutics,” said Vipin K. Garg, Ph.D., President
& CEO of Tranzyme Pharma. “GI motility disorders are
characterized by large, underserved markets with a few or poor
performing therapies. In contrast to most current treatments
under development, Tranzyme is focused on developing
first-in-class products that act on targets directly involved in
regulating GI motility.”
|
|
|
